The new drug functions by fooling the parathyroid glands into considering the levels of calcium in the bloodstream are greater than they actually are, therefore the glands stop generating extra parathyroid hormone. Through the 26-week trial, Cinacalcet was given to 371 patients, and 370 received a placebo. Forty-three % of those who received the drug showed regular parathyroid hormone levels at the final end of the trial, versus simply five % of these who got the placebo.. Cinacalcet drug more lucrative than a placebo in treating hyperparathyroidism Research led by Saint Louis University physicians has shown a new drug might help control one of the most common side effects of kidney disease.Food and Drug Administration . It really is a enjoyment to be working with two great CMOs. Both have proven track information in having the ability to meet exacting standards and timelines, Dr. Andrew Heaton, Novogen Group Vice-President, Drug Discovery and Manufacture, said. Both also have a strong history of assisting companies with the advancement of formulations, from pre-clinical to commercial manufacture. Having romantic relationships with such companies also meets our long term corporate goal of seeing Cantrixil improvement from an experimental to a commercial product.